Importantly, our study provides evidence that the CRISPR/Cas9 genome editing system is a simple, cheap and fast tool by which to manipulate genomes that are expected to have a broader therapeutic application in insulin resistance by modulating the deregulated genetic network of the insulin signaling pathway (Figure 3). The gene discussed is INS; the disease is Insulin resistance.